DGAP-News: Evotec AG / Key word(s): AGM/EGM
2016-06-14 / 16:43
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
APPROVAL OF ALL AGENDA ITEMS WITH THE REQUIRED MAJORITY
ACTIONS OF MANAGEMENT BOARD AND SUPERVISORY BOARD APPROVED
APPOINTMENT OF ERNST & YOUNG GMBH WIRTSCHAFTSPRÜFUNGSGESELLSCHAFT AS
AUDITOR
NEW RESOLUTION AUTHORISING THE ISSUANCE OF CONVERTIBLE BONDS AND/OR
WARRANT-LINKED BONDS, PARTICIPATION RIGHTS AND/OR INCOME BONDS AND CREATION
OF NEW CONTINGENT CAPITAL APPROVED
Hamburg, Germany, 14 June 2016:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced that its shareholders approved all proposals the Company's
Management put to vote at the Company's Annual General Meeting, which took
place today, with the required majority.
The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented
the Company's performance for the year 2015 and provided the shareholders
with an update regarding future developments in his speech "The right
translation at Evotec". Furthermore, Enno Spillner, who will become Chief
Financial Officer of Evotec AG effective 18 July 2016, was introduced.
At the Annual General Meeting 2016, the actions of the members of the
Management Board and the Supervisory Board for the fiscal year 2015 were
approved. The Annual General Meeting also approved a new resolution
authorising the issuance of convertible bonds and/or warrant-linked bonds,
participation rights and/or income bonds and the creation of new contingent
capital. Moreover, the Annual General Meeting passed the other agenda items
requiring shareholders' approval, hereunder amendments to the Articles of
Association and the appointment of Ernst & Young GmbH
Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for fiscal year
2016.
At the ordinary Annual General Meeting 2016 of Evotec AG, 36.34% of the
voting capital was present.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes,
with Pfizer in the field of tissue fibrosis and with Second Genome in the
field of inflammatory diseases. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
---------------------------------------------------------------------------
2016-06-14 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX
End of News DGAP News Service